About PeptideAdvance

PeptideAdvance is an independent peptide research and education resource. We publish plain-language analysis of peptide mechanisms, clinical evidence, regulatory status, and the broader research landscape.

We are not a peptide vendor. We do not sell, distribute, or fulfill peptide orders of any kind. We do not have an affiliate relationship with peptide manufacturers or compounding pharmacies.

Our editorial process: every peptide and article on PeptideAdvance is reviewed against published literature, FDA regulatory positions, and the current state of clinical research. We attempt to distinguish strong evidence from weak evidence, claims from data, and approved drugs from investigational compounds.

What we believe: peptide research is a serious area of medical and biological inquiry that has produced both genuinely transformative drugs (semaglutide, tirzepatide) and a long tail of marketing claims with thin underlying data. Both deserve clear-eyed analysis. Hyperbole and dismissal are equally unhelpful.

We update content regularly as new research, regulatory positions, and clinical data emerge. The peptide landscape in 2026 is materially different from 2022, and 2028 will be materially different from 2026.

Contact: [email protected]